Vaccination against atherosclerosis: An overview

Area of Science:

• Cardiovascular Research
• Immunology
• Vaccine Development

Background:

• Atherosclerosis is a global health burden, characterized by inflammation and immune responses.
• Current treatments focus on cardiovascular risk factors, highlighting the need for novel therapeutic strategies.
• Vaccination presents a promising approach to attenuate atherosclerosis, inflammation, and lipid levels.

Purpose of the Study:

• To explore vaccination as a novel strategy for treating atherosclerosis.
• To review existing vaccination methods and identify challenges in antigen and adjuvant selection.
• To highlight the need for further research into human clinical trials for atherosclerosis vaccines.

Main Methods:

• Review of various vaccination methods investigated, primarily in murine models.
• Analysis of different antigens used in experimental atherosclerosis vaccines, including OxLDL, apoB100, CETP, PCSK9, HSP60, MHC-II-derived peptides, and interleukins.
• Consideration of DNA-based vaccination as an emerging approach.

Main Results:

• Experimental vaccination studies in mice have shown promising results in reducing atherosclerosis, inflammation, and lipid concentrations.
• Identification of challenges in selecting appropriate antigens and adjuvants for effective vaccination.
• DNA-based vaccination shows potential as a new avenue for atherosclerosis treatment.

Conclusions:

• Vaccination is a promising strategy for atherosclerosis, with successful preclinical results.
• Further research is crucial to address gaps in human clinical trials, including antigen selection, delivery methods, safety, and scheduling.
• Developing effective, economical, and accessible vaccination methods is essential for future clinical application.